Full-Time
Senior Manager
Lean & Continuous Improvement
Posted on 12/13/2025
Stryker
10,001+ employees
Manufactures orthopedic and surgical medical devices
No salary listed
Cork, Ireland
In Person
 Operations & Logistics (1) |
|---|
- B.S in Engineering, Science, Business or other related discipline with 10 or more years’ experience; or related masters degree with 6 or more years of experience; or PhD with 4 or more years of experience may also be desirable.
- Minimum 5 years’ experience in a manufacturing environment utilizing lean principles.
- Demonstrated experience leading/deploying OpEx initiatives and coaching at site, and functional level.
- Lead development of a detailed operational excellence strategy for the business. Leverage value stream mapping to create and execute operational, technology, and resource roadmaps.
- Lead a culture of lean, innovation, continuous Improvement (CI) & process excellence, including initiatives such as Managing for Daily Improvement (MDI), 6S, human error reduction, problem solving and value stream mapping.
- Deliver the Stryker Production System (SPS) for daily management, problem solving and leader standard work.
- Influence professional teams in a multi-site, matrix model. Talent based management, actively promote performance management and coaching. Champion development and career pathing.
- Drive high levels of employee engagement through cultural change & inclusion in the OpEx journey.
- Conduct OpEx assessments to understand site, and talent capabilities. Build capability through training, coaching & people development. Ensure implementation of identified tools, processes, and systems. Oversee Lean Six Sigma greenbelt/blackbelt deployment programs.
- As part of the leadership team, accountable for the sites’ cost reduction, delivery, quality, and safety targets.
- Develop innovative operational excellence solutions to complex business & technology challenges where analysis of situations or data requires an in-depth evaluation of variable factors. Solutions may require the regular use of ingenuity and creativity.
- Assume the role of technical & cultural mentor for various functions. Be the champion for promoting OpEx wins through various communication channels.
- Monitor and control progress of work ensuring sound application of principles, delivery to strategic intent and the appropriate use of practices and tools.
- Drive continuous improvement through the greater integration of digital systems throughout the plants (use centrally generated reports, maximize the efficiency of technologies, budget planning, capacity evaluations, systems etc.).
- Establish a strategy & system for process control & monitoring. Evaluate process to ensure maximum utilisation of equipment and floor space, minimise handling and optimum process flow.
- Influence others in an operations environment and quickly gain respect and support from site leadership team, operators, and fellow CI site reps.
- Develop and implement global strategies, driving meaningful change across the business. You’ll lead strategy deployment efforts using Hoshin Kanri or similar techniques.
- Manage budgets effectively, using sound financial judgment to deliver results. You’ll identify opportunities for cost reduction and lead ongoing continuous improvement initiatives.
- Collaborateacross all levels and functions, building strong relationships and trust while working both independently and as part of a team.
- Make timely, wellinformed decisions and take a proactive approach to problemsolving. You’ll act with a sense of urgency and accountability in everything you do.
- PhD with 4 or more years of experience may also be desirable.
- Broad based business experience in high performance multi-national enterprise, at least 5 years of which has been spent in operations and/or technical leadership level in Medical Device or other highly regulated industries very advantageous.
- Digitalisation and automation experience / exposure is preferable.
- Lean education background, preferably Black Belt level.
Stryker designs, manufactures, and sells medical devices across multiple areas, including surgical equipment, neurotechnology, and orthopedic implants, to hospitals and clinics worldwide. Its products are developed through engineering and clinical input, then manufactured and distributed to healthcare providers who use them during procedures to improve patient care and surgical efficiency. Stryker differentiates itself from competitors with a broad, integrated portfolio, a global sales and service network, and a strong emphasis on quality and ongoing product development to support safer, more efficient procedures. The company’s goal is to advance patient outcomes by delivering reliable, effective medical devices that expand access to care globally.
Company Size
10,001+
Company Stage
IPO
Headquarters
Kalamazoo, Michigan
Founded
1941
Simplify's Take
What believers are saying
- Robotic surgery leadership drives double-digit sales growth through 2025.
- India Trident II launch targets aging population's rising hip surgeries.
- Peripheral vascular expansion via IVL meets growing arterial disease demand.
What critics are saying
- Handala cyberattack on March 11 delays ortho supply chain 3-6 months.
- Zimmer Biomet Persona IQ erodes ortho share with real-time analytics.
- J&J Velys captures 25% more knee procedures from Mako in 6-12 months.
What makes Stryker unique
- Stryker holds 39.1% US market share in orthopedic product manufacturing.
- Trident II Acetabular System integrates Mako SmartRobotics for hip replacements.
- Amplitude Vascular Systems acquisition adds CO₂ IVL for peripheral arteries.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Medical & prescription plans
Supplemental health benefits
Flexible Spending accounts
Employee Assistance Program
Short-term & long-term disability
Tuition reimbursement
401(k) plan
Employee Stock Purchase Plan
Company News
Distalmotion targets ASC gynecology programs with new FDA filing Distalmotion has submitted a 510(k) application to the FDA seeking to expand the label of its Dexter robotic surgery system into additional gynecological indications, the company announced April 1. The filing covers sacrocolpopexy, sacrocervicopexy and endometriosis resection. Sacrocolpopexy and sacrocervicopexy are procedures used to treat pelvic…
Stryker Corporation has signed a definitive agreement to acquire Amplitude Vascular Systems, a Boston-based medical technology company developing next-generation intravascular lithotripsy technology for treating calcified peripheral arterial disease. Financial terms were not disclosed. AVS's technology uses pulsed CO₂-generated pressure waves delivered through a balloon catheter to fracture calcium deposits. The platform aims to enhance catheter deliverability, treatment speed and therapy efficiency. The acquisition will strengthen Stryker's peripheral vascular portfolio and expand its presence in arterial disease treatment. Stryker CEO Kevin Lobo said the deal advances the company's vision to build a comprehensive peripheral vascular platform addressing significant clinical needs. IVL technology is experiencing strong growth as physicians increasingly adopt it for calcium modification in complex cardiovascular procedures. The transaction remains subject to customary closing conditions.
Stryker has raised $120 million in a Series C round led by Ribbit Capital, valuing the medical technology company at $1.45 billion. The funding comes despite shares declining 7.6% over the past six months, outperforming the industry's 19.7% drop. The company delivered 11% organic sales growth in Q4 2025 and 10.3% for the full year, marking its fourth consecutive year of double-digit growth. Performance was broad-based across its Orthopaedics, MedSurg and Neurotechnology segments, driven by strong procedural volumes and favourable demographics. Stryker achieved over 100 basis points of operating margin expansion for the second consecutive year despite tariff pressures. The company enters 2026 with a robust capital equipment backlog, though rising interest costs and tariffs present near-term challenges. Analysts maintain a Hold rating on the stock.
Stryker shares fell 9% to $339 following a destructive cyberattack by Iranian-linked group Handala that wiped over 200,000 systems and disrupted manufacturing and shipping operations across 56,000 employees in 61 countries. The medical technology company confirmed disruptions to order processing but stated there was no indication of ransomware. Unlike typical ransomware attacks, this wiper attack permanently deleted data rather than holding it for ransom, complicating recovery efforts. The incident threatens Stryker's 8% to 9.5% organic growth guidance for 2026 if operations fail to normalise quickly. Stryker generated $25 billion in revenue in 2025 with $4.283 billion in free cash flow and holds $4 billion in cash. Analysts maintain a consensus price target of $424.89 with 22 buy ratings and no sell ratings among 30 covering analysts.
Stryker reported Q4 revenues of $7.17 billion, up 11.4% year-over-year and exceeding analyst expectations by 0.8%. The medical device manufacturer, which impacts over 150 million patients annually through its orthopaedics, surgical tools, neurotechnology and patient care solutions, delivered what CEO Kevin Lobo called "an outstanding finish to 2025". The company achieved double-digit sales and adjusted earnings per share growth for both the quarter and full year, whilst expanding adjusted operating margin by at least 100 basis points for the second consecutive year. Across the medical devices and supplies sector, the six diversified stocks tracked reported mixed Q4 results. As a group, revenues beat consensus estimates by 1.9%, though share prices have declined an average of 5.1% since the latest earnings announcements.